Eisai's Perampanel Shows Positive Phase III Results For Epilepsy Following Failure As Parkinson's Treatment
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Positive Phase III results in epilepsy for the AMPA receptor antagonoist perampanel set it on a rebound following Eisai's decision two years ago to abandon development of the drug in Parkinson's disease